Header

UZH-Logo

Maintenance Infos

Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO


Meier, Christian; Uebelhart, Brigitte; Aubry-Rozier, Bérengère; Birkhäuser, Martin; Bischoff-Ferrari, Heike A; Frey, Diana; Kressig, Reto W; Lamy, Olivier; Lippuner, Kurt; Stute, Petra; Suhm, Norbert; Ferrari, Serge (2017). Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO. Swiss Medical Weekly, 147:w14484.

Abstract

Antiosteoporotic drugs are recommended in patients with fragility fractures and in patients considered to be at high fracture risk on the basis of clinical risk factors and/or low bone mineral density. As first-line treatment most patients are started with an antiresorptive treatment, i.e. drugs that inhibit osteoclast development and/or function (bisphosphonates, denosumab, oestrogens or selective oestrogen receptor modulators). In the balance between benefits and risks of antiresorptive treatment, uncertainties remain regarding the optimal treatment duration and the management of patients after drug discontinuation. Based on the available evidence, this position statement will focus on the long-term management of osteoporosis therapy, formulating decision criteria for clinical practice.

Abstract

Antiosteoporotic drugs are recommended in patients with fragility fractures and in patients considered to be at high fracture risk on the basis of clinical risk factors and/or low bone mineral density. As first-line treatment most patients are started with an antiresorptive treatment, i.e. drugs that inhibit osteoclast development and/or function (bisphosphonates, denosumab, oestrogens or selective oestrogen receptor modulators). In the balance between benefits and risks of antiresorptive treatment, uncertainties remain regarding the optimal treatment duration and the management of patients after drug discontinuation. Based on the available evidence, this position statement will focus on the long-term management of osteoporosis therapy, formulating decision criteria for clinical practice.

Statistics

Citations

Dimensions.ai Metrics

Altmetrics

Downloads

72 downloads since deposited on 12 Sep 2017
72 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine
04 Faculty of Medicine > University Hospital Zurich > Clinic for Geriatric Medicine
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:5 September 2017
Deposited On:12 Sep 2017 16:00
Last Modified:19 Feb 2018 08:38
Publisher:EMH Swiss Medical Publishers
ISSN:0036-7672
OA Status:Gold
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.4414/smw.2017.14484
PubMed ID:28871570

Download

Download PDF  'Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO'.
Preview
Content: Published Version
Filetype: PDF
Size: 605kB
View at publisher
Licence: Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)